Preface: An Overview of Immunotoxins and Cytotoxins in Clinical Trials. PART 1. PSEUDOMONAS EXOTOXIN (PE)-BASED IMMUNOTOXINS/CYTOTOXINS. Targeting of Pseudomonas Exotoxin-based Immunotoxins to Hematologic Malignancies. Interleukin-4-targeted Cytotoxin for Recurrent Glioblastoma Therapy. Interleukin-13 Receptors and Development of IL-13-Pseudomonas Exotoxin for Human Cancer Therapy. PART 2. RICIN-BASED IMMUNOTOXINS/CYTOTOXINS. Ricin Immunotoxins in Lymphomas. PART 3. DIPHTHERIA TOXIN (DT)-BASED IMMUNOTOXINS/CYTOTOXINS. Diphtheria-based Immunotoxins: Targeting Overexpressed Interleukin-13 Receptor and Urokinase-type Plasminogen Activator Receptor on Glioblastoma Multiforme. DAB389IL-2 (Ontak): Development and Therapeutic Applications. Transferrin Diphtheria Toxin for Brain Tumor Therapy. GM-CSF Receptor Targeted Therapy of Human Leukemia. VEGF-diphtheria toxin for Targeting of Tumor Blood Vessels. PART 4. MISCELLANEOUS. cBR-96-doxorubicin (SGN-15) for Metastatic Breast Cancer Therapy. Anti-CD33 Calicheamicin Immunoconjugate Therapy of Acute Myeloid Leukemia.
Koji Kawakami, Bharat B. Aggarwal, Raj K. Puri
"With a focus on clinical developmental approaches to the use of cytotoxins and immunotoxins, this book discusses exciting possibilities for cancer research. It is a valuable resource for scientists, researchers, and clinicians involved in the development of new treatments that can help keep cancer under control, and may ultimately lead to a cure." – In Anticancer Research, September/ October 2008, Vol. 27, No. 5A
|
Ask a Question About this Product More... |
|
